Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

214 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The treatment-naive microbiome in new-onset Crohn's disease.
Gevers D, Kugathasan S, Denson LA, Vázquez-Baeza Y, Van Treuren W, Ren B, Schwager E, Knights D, Song SJ, Yassour M, Morgan XC, Kostic AD, Luo C, González A, McDonald D, Haberman Y, Walters T, Baker S, Rosh J, Stephens M, Heyman M, Markowitz J, Baldassano R, Griffiths A, Sylvester F, Mack D, Kim S, Crandall W, Hyams J, Huttenhower C, Knight R, Xavier RJ. Gevers D, et al. Among authors: Kugathasan S. Cell Host Microbe. 2014 Mar 12;15(3):382-392. doi: 10.1016/j.chom.2014.02.005. Cell Host Microbe. 2014. PMID: 24629344 Free PMC article.
Inflammatory bowel diseases (IBDs), including Crohn's disease (CD), are genetically linked to host pathways that implicate an underlying role for aberrant immune responses to intestinal microbiota. ...
Inflammatory bowel diseases (IBDs), including Crohn's disease (CD), are genetically linked to host pathways that implicate an underly …
Intrinsic hyperreactivity of mucosal T cells to interleukin-2 in pediatric Crohn's disease.
Kugathasan S, Willis J, Dahms BB, O'Riordan MA, Hupertz V, Binion DG, Boyle JT, Fiocchi C. Kugathasan S, et al. J Pediatr. 1998 Nov;133(5):675-81. doi: 10.1016/s0022-3476(98)70111-8. J Pediatr. 1998. PMID: 9821428
Mucosal T cells are particularly important in the pathogenesis of Crohn's disease (CD). We investigated the response of T cells in CD and other intestinal inflammatory conditions to interleukin-2 (IL-2), a cytokine essential for T-cell activation, growth, and function. ...
Mucosal T cells are particularly important in the pathogenesis of Crohn's disease (CD). We investigated the response of T cells in CD …
Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease.
Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG. Kugathasan S, et al. Am J Gastroenterol. 2000 Nov;95(11):3189-94. doi: 10.1111/j.1572-0241.2000.03263.x. Am J Gastroenterol. 2000. PMID: 11095340 Clinical Trial.
OBJECTIVES: Tumor necrosis factor-alpha plays a central role in chronic intestinal inflammation of Crohn's disease. Targeting this cytokine with the chimeric monoclonal antibody infliximab has emerged as an effective form of therapy in adult Crohn's disease patients. We sought to determine whether infliximab treatment would benefit pediatric patients with medically refractory Crohn's disease. ...
OBJECTIVES: Tumor necrosis factor-alpha plays a central role in chronic intestinal inflammation of Crohn's disease. Targeting this cy …
Successful desensitization and therapeutic use of infliximab in adult and pediatric Crohn's disease patients with prior anaphylactic reaction.
Puchner TC, Kugathasan S, Kelly KJ, Binion DG. Puchner TC, et al. Among authors: Kugathasan S. Inflamm Bowel Dis. 2001 Feb;7(1):34-7. doi: 10.1097/00054725-200102000-00005. Inflamm Bowel Dis. 2001. PMID: 11233658
Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulizing Crohn's disease (CD), but can be associated with the development of severe allergic reactions during retreatment, precluding further use of the medication. ...
Infusion of the antitumor necrosis factor-alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory a …
Infliximab retreatment in adults and children with Crohn's disease: risk factors for the development of delayed severe systemic reaction.
Kugathasan S, Levy MB, Saeian K, Vasilopoulos S, Kim JP, Prajapati D, Emmons J, Martinez A, Kelly KJ, Binion DG. Kugathasan S, et al. Am J Gastroenterol. 2002 Jun;97(6):1408-14. doi: 10.1111/j.1572-0241.2002.05784.x. Am J Gastroenterol. 2002. PMID: 12094858
OBJECTIVES: Although effective in the treatment of refractory Crohn's disease, episodic retreatment with the antitumor necrosis factor a chimeric monoclonal antibody infliximab (Remicade, Centocor, Malvern, PA) can be associated with severe acute and delayed systemic reactions. ...Delayed systemic reactions, characterized by arthralgia, fever, and myalgia requiring corticosteroid treatment, were found exclusively in adults (age > 17 yr) and occurred in eight patients treated for luminal Crohn's disease. ...
OBJECTIVES: Although effective in the treatment of refractory Crohn's disease, episodic retreatment with the antitumor necrosis facto …
Guidelines for immunizations in patients with inflammatory bowel disease.
Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, Orenstein W. Sands BE, et al. Among authors: Kugathasan S. Inflamm Bowel Dis. 2004 Sep;10(5):677-92. doi: 10.1097/00054725-200409000-00028. Inflamm Bowel Dis. 2004. PMID: 15472534
During the past 2 decades, medical therapy for Crohn's disease (CD) and ulcerative colitis (UC) has grown to incorporate a variety of immunesuppressing agents. ...
During the past 2 decades, medical therapy for Crohn's disease (CD) and ulcerative colitis (UC) has grown to incorporate a variety of …
CARD15 gene mutations and risk for early surgery in pediatric-onset Crohn's disease.
Kugathasan S, Collins N, Maresso K, Hoffmann RG, Stephens M, Werlin SL, Rudolph C, Broeckel U. Kugathasan S, et al. Clin Gastroenterol Hepatol. 2004 Nov;2(11):1003-9. doi: 10.1016/s1542-3565(04)00452-5. Clin Gastroenterol Hepatol. 2004. PMID: 15551253
BACKGROUND & AIMS: The risk for Crohn's disease (CD) is determined in part by genetic factors. Three recently described mutations in the CARD15(NOD2) gene have been associated with adult-onset CD. ...
BACKGROUND & AIMS: The risk for Crohn's disease (CD) is determined in part by genetic factors. Three recently described mutations …
A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease.
Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL. Bousvaros A, et al. Among authors: Kugathasan S. Inflamm Bowel Dis. 2005 Sep;11(9):833-9. doi: 10.1097/01.mib.0000175905.00212.2c. Inflamm Bowel Dis. 2005. PMID: 16116318 Clinical Trial.
Probiotics are widely used by patients with Crohn's disease (CD) in an attempt to improve their health, but few controlled studies have been done to evaluate the efficacy of these therapies. ...
Probiotics are widely used by patients with Crohn's disease (CD) in an attempt to improve their health, but few controlled studies ha …
214 results
Jump to page
Feedback